Clinical Trial Update: Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial is evaluating the safety and potential efficacy of NK520 in pediatric patients with relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• NK520

Snippet

Sponsor: Base Therapeutics (Shanghai) Co., Ltd. | Conditions: Relapsed/Refractory Acute Myeloid Leukemia | EARLY_Phase 1 | Status: RECRUITING